12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
Click on a name to see Biography
Alan D. Snow, PhD (Chairman, President, & CSO) is the Chairman of the Board. He served as a Research Associate Professor of Pathology at the University of Washington, and was an integral part of the Alzheimer's Disease Research Center. Dr. Snow is a worldwide recognized authority on the role of proteoglycans in Alzheimer's and amyloid diseases, with over 25 years of experience in this area of research. At the University of Washington, Dr. Snow was the first to identify and demonstrate specific proteoglycans in amyloid deposits in Alzheimer's disease.
Dr. Snow has co-authored several publications with Dr. Stanley Prusiner, a Nobel laureate, and was the first to identify specific proteoglycans in the brain amyloid deposits in a variety of prion diseases. He is the author of more than 50 scientific publications, is an inventor of over 260 issued patents, and has presented his research on amyloid disease and proteoglycans at over 120 scientific meetings. He holds a BS in Chemistry/Biology from Bowling Green State University in Ohio, a MS in Anatomy from University of Western Ontario (London, Ontario, Canada) and a PhD in Pathology from Queen's University (Kingston, Ontario, Canada).
Dennis L. McCurley, MBA, PhD (COO/CFO) is responsible for the daily operations at ProteoTech.
Dr. McCurley has held various senior management positions over the past 30 years including VP-Franchising, VP-Regional Manager with First Interstate Bancorp and CEO of Capital Access One. He earned his MBA from the University of Southern California in finance and holds a PhD in Management and Organizational Behavior. Dr. McCurley has been very involved in the community by serving on several nonprofit boards. Dr. McCurley has been a guest lecturer at the University of Washington in Organizational Behavior and Business Ethics. He was also a founding member of several start-up companies before joining ProteoTech in 1997.
Rebecca Eagen, PhD, (Director of Intellectual Property) is responsible for managing the extensive and growing IP portfolio of the Company. Dr. Eagen is a Registered Patent Agent in the US and Canada and has specialized in pharmaceutical and biotechnology patents. She holds a PhD in Molecular Biology and Biochemistry from the University of British Columbia, Vancouver, BC.
Roger S. Flugel, PhD (CBO) is a recent addition to ProteoTech as Chief Business Officer.
Dr. Roger Flugel was previously CEO of TheraVida (Mountain View, CA) from 2007 to 2013 and prior to that was a Principal with Sanderling Ventures, serving in a variety of roles as Director, Chairman, CEO, and board observer of several portfolio companies. While at Sanderling, he helped complete strategic corporate transactions for Kadmus (acquired by Schering-Plough, now Merck) and Aderis (acquired by Schwarz Pharma, now UCB). Prior to Sanderling, Dr. Flugel served as the Director of Venture Analysis at HealthCare Ventures. Dr. Flugel is now responsible for representing ProteoTech in all business transactions and partnerships. Dr. Flugel received his Ph.D. in Biophysics from Harvard University, conducting his research in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.
Joann L. Data, PhD, MD (CMO) is a recent addition to ProteoTech as Chief Medical Officer.
Dr. Joann Data has held many clinical and regulatory affairs positions at a variety of different biotechnology and pharmaceutical companies including most recently Amylin Pharmaceuticals where she served as Senior Vice President of Corporate Assignments as well as Senior Vice President of Regulatory Affairs and Quality Assurance. She was the Executive Vice President of Product Development and Regulatory Affairs for CoCensys and Corporate Vice President for Worldwide Pharmaceutical Regulatory Affairs and Project Management at the Upjohn Company. Dr. Data has been a consultant full time since 2006 within the biotech arena and venture capital groups. She has served as Chief Medical Officer to CoDa Therapeutics, Xytis, Cortex and other biotech companies. Dr. Data has also served on the Board of Directors of Nventa and is currently serving on the advisory boards of Washington University School of Medicine and Vanderbilt University School of Medicine. Data received her M.D. at Washington University School of Medicine and her house officer training in Internal Medicine at the State University of New York at Buffalo followed by her Ph.D. in Pharmacology and Fellowship in Clinical Pharmacology at Vanderbilt.
Scientific Advisory Board
Board of Directors
Alan D.Snow, PhD - Chairman, President, and Chief Scientific Officer: Dr. Snow is the Founder and Chairman of the Company's Board of Directors. He previously served as a Research Associate Professor of Pathology at the University of Washington, and is a world-recognized authority on the role of proteoglycans in Alzheimer's and amyloid diseases. He holds a BS in Biology/Chemistry from Bowling Green State University in Ohio, an MS in Anatomy from University of Western Ontario (London, Ontario, Canada), and a PhD in Pathology from Queen's University (Kingston, Ontario, Canada). At Queen's University, Dr. Snow worked in the laboratory of Dr. Robert Kisilevsky. Dr. Snow's thesis work led to new discoveries concerning the pathogenic role that proteoglycans and glycosaminoglycans play in amyloid diseases.
At the University of Washington, Dr. Snow was the first to identify and demonstrate specific proteoglycans in amyloid deposits in Alzheimer's disease. Dr. Snow has co-authored several publications with Dr. Stanley Prusiner, a Nobel laureate, and was the first to identify specific proteoglycans in the brain amyloid deposits in a variety of prion diseases. Dr. Snow is the author of more than 50 scientific publications and has presented his research on amyloid disease and proteoglycans at over 120 scientific meetings. Dr. Snow is also a co-inventor on over 300 patents, including over 260 issued patents (in the US and Internationally).
Dr. Snow founded ProteoTech in 1996, then left the University of Washington in 1999 to serve as the Company's Chairman, President, acting CEO and CSO. He was instrumental in personally writing and acquiring over $16 million in grant funding from the NIH SBIR and The Michael J. Fox Foundation for Parkinson's research LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) program. He helped hire corporate and patent lawyers, as well as regulatory and scientific advisors, and recruited world-class research scientists and key management and consultant positions for the Company. He helped negotiate and write/edit business contracts and agreements for various contract research organizations and university collaborations, and guided major drug development programs for ProteoTech in Alzheimer's, Parkinson's, type 2 diabetes and systemic amyloidosis. He helped write and guided patent lawyers and patent agents on more than 300 patents pertaining to new therapeutics and diagnostics platform for amyloid diseases and proteoglycan technologies.
Dennis L. McCurley, MBA, PhD – Chief Operating Officer and Chief Financial Officer: Prior to joining ProteoTech, Dr. McCurley has held senior management positions with various companies. Those positions include VP-Franchising, VP-Regional Manager with First Interstate Bancorp, VP-District Manager with Wells Fargo Bank and CEO of Capital Access One. Dr. McCurley has also participated in establishing and growing several innovative companies prior to ProteoTech.